SWOG clinical trial number
SWOG-9510
Evaluation of Topotecan in Hormone Refractory Prostate Cancer, Phase II
Closed
Phase
Accrual
78%
Published
Abbreviated Title
Advanced Prostate
Activated
11/01/1996
Closed
08/15/1999
Research committees
Genitourinary Cancer
Publication Information Expand/Collapse
2002
SWOG-9510: Evaluation of topotecan in hormone-refractory prostate cancer: a Southwest Oncology Group study
Other Clinical Trials
SWOG Clinical Trial Number
S2210
S2210, "Targeted Neoadjuvant Treatment for Patients with Localized Prostate Cancer and Germline DNA Repair Deficiency"
Research Committee(s)
Genitourinary Cancer
Activated
08/14/2023
Accrual
2%
Open
Phase
SWOG Clinical Trial Number
S2200
S2200, A Phase II Randomized Trial of Cabozantinib with or Without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma: PAPMET2
Research Committee(s)
Genitourinary Cancer
Activated
09/19/2022
Accrual
8%
Open
Phase
SWOG Clinical Trial Number
CTSU/A031901
Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: A Randomized Phase 3 Non-Inferiority Trial
Research Committee(s)
Genitourinary Cancer
Activated
05/01/2021
Open
Phase